This statistic depicts the percentage of the U.S. population who had anxiety disorders from 1990 to 2021, by gender. According to the data, 5.2 percent of males and 9.3 percent of females had anxiety disorders in 2021.

In 2021, it was estimated that around 4.4 percent of the global population suffered from an anxiety disorder. This statistic depicts the percentage of the population worldwide who had anxiety disorders from 1990 to 2021.

This statistic depicts the percentage of the U.S. population who had anxiety disorders from 1990 to 2021. According to the data, 6.9 percent of the population suffered from an anxiety disorder as of 2021.

A survey conducted in 2022 found that young adults aged between 18 and 24 were more likely to suffer from moderate to severe stress, depression, and anxiety symptoms. That year, around 66 percent of respondents from this age group reported stress-related symptoms, while 25 percent of those aged 65 and older had similar symptoms. Similar age group trends were also noted for negative effects on wellbeing from feelings of loneliness. Additionally, fewer men than women were likely to report having mental health conditions such as stress, anxiety, and depression. Anxiety, depression, and stress in Europe In Europe, there is a notable variation in the prevalence of mental illnesses. Throughout the epidemic, depression and anxiety increased in all EU nations, affecting young people, particularly young women and those in financial difficulties. A study published by the OECD reported that 55 percent of adults residing in the EU were at risk of depression in 2022. Another study, published in the same year, found that more than half of the respondents surveyed in Ireland, the United Kingdom, and Italy had reported experiencing stress. Anxiety, depression, and loneliness in the U.S. In the United States, anxiety, depression, and loneliness are prevalent issues affecting a significant portion of the population. According to a survey done in 2022, one-third of U.S. adults aged between 18 and 29 years mentioned that they “always” or “often” felt depressed or lonely in the past year. Over half of U.S. adults in the same age group reported that they felt anxious. Furthermore, adults with lower household incomes were more likely than those with higher household incomes to mention that they felt anxious, lonely, or depressed.

Content

This dataset contains behavioural, psychophysiological, and demographic data collected from 193 preschool children aged 3-5 years to predict the risk of anxiety disorders. The data was originally collected for the research paper "Quantifying Risk for Anxiety Disorders in Preschool Children: A Machine Learning Approach" published in the Journal of Child Psychology and Psychiatry. This dataset can be used to develop machine learning models to quantify anxiety risk in young children.

Included Files

Training Data.xlsx: Includes 130 randomly selected participants, which is about 70% of the full dataset. Testing Data.xlsx: Has the remaining 30% of participants, which is 63 children.

Dataset Glossary (Column-wise)

• ID - Unique identifier for each child
• Age - Age of child in years
• Sex - Male or female
• Race - Self-reported race/ethnicity
• SES - Socioeconomic status composite score
• BAS_B - Behavioral inhibition questionnaire
• BAS_F - Fearfulness subscale
• ARI - Anxiety-related inhbition scale
• ERC_LER - Emotion regulation checklist - lability/negativity subscale
• ERC_ERS - Emotion regulation checklist - emotion regulation subscale
• SDQ_ES - Strengths & difficulties questionnaire - emotional symptoms subscale
• Heart_Rate - Average heart rate during tasks
• SCL - Average skin conductance level
• Cortisol - Cortisol reactivity score
• SAD - Seasonal affective disorder
• GAD - Generalized Anxiety Disorder
• Anxiety_DX - Anxiety disorder diagnosis at 12-month follow-up (0/1)

Acknowledgements

If you use this dataset in your research, please credit the data has been made publicly available through the Harvard Dataverse repository (Carpenter, 2016). Details on the study methodology and cohort are published in Carpenter et al., 2019 in the Journal of Child Psychology and Psychiatry. This dataset can be accessed at https://doi.org/10.7910/DVN/N42LWG and used under a CC0 1.0 Universal license that supports open scientific collaboration.

This statistic depicts the percentage of the population worldwide who had anxiety disorders from 1990 to 2019, by gender. According to the data, around **** percent of males and **** percent of females suffered from an anxiety disorder as of 2019.

This is a development key figure, see questions and answers on kolada.se for more information. Share (%) population aged 16-84 with severe anxiety, anxiety or anxiety. The results are taken from the national survey Health on equal terms (National Institute of Public Health). The data refers to year T-2 to year T. Data is available according to gender breakdown.

Anti-Anxiety Drugs Market Outlook

The global anti-anxiety drugs market size was valued at approximately USD 12.4 billion in 2023 and is expected to reach USD 18.7 billion by 2032, growing at a compound annual growth rate (CAGR) of 4.6% during the forecast period. This market is driven by the increasing prevalence of anxiety disorders, growing awareness about mental health, and advancements in pharmacotherapy. The rising social acceptance of mental health issues and the development of novel drugs are expected to further propel market growth.

One of the primary growth factors for the anti-anxiety drugs market is the escalating prevalence of anxiety disorders across the globe. Factors such as increasing stress levels due to fast-paced life, work pressure, and personal relationship issues contribute significantly to this rise. According to the World Health Organization (WHO), anxiety disorders are among the most common mental health disorders, affecting millions of people worldwide. This escalating prevalence necessitates the development of effective treatments, thereby driving the demand for anti-anxiety drugs.

Another significant growth factor is the growing awareness and acceptance of mental health issues. Over the past decade, there has been a significant shift in public perception regarding mental health, leading to increased diagnoses and treatment of anxiety disorders. Campaigns, social media platforms, and celebrities opening up about their mental health struggles have played a crucial role in breaking the stigma associated with mental health disorders. This has resulted in more individuals seeking medical help, thereby boosting the demand for anti-anxiety medications.

The continuous advancements in pharmacotherapy also significantly contribute to the market's growth. Pharmaceutical companies are investing heavily in research and development (R&D) to develop novel drugs with fewer side effects and improved efficacy. Innovations such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) have transformed the treatment landscape for anxiety disorders. Additionally, the introduction of personalized medicine approaches and the development of new drug delivery systems are anticipated to further enhance market growth.

Regionally, North America holds a prominent share in the global anti-anxiety drugs market, primarily due to the high prevalence of anxiety disorders and the presence of well-established healthcare infrastructure. Europe also represents a significant market, driven by increasing awareness and the rising incidence of mental health issues. The Asia Pacific region is expected to witness the fastest growth during the forecast period, attributed to the growing population, increasing healthcare expenditure, and rising awareness about mental health. Latin America and the Middle East & Africa are also expected to contribute to the market growth, albeit at a slower pace, due to improving healthcare facilities and increasing recognition of mental health issues.

Drug Class Analysis

Benzodiazepines, a class of drugs commonly prescribed for anxiety disorders, hold a significant share in the anti-anxiety drugs market. Benzodiazepines work by enhancing the effect of a neurotransmitter called gamma-aminobutyric acid (GABA), which induces a calming effect. They are highly effective for short-term relief of severe anxiety symptoms and are often used for conditions such as panic disorder and generalized anxiety disorder. However, their potential for dependence and side effects such as drowsiness and dizziness have led to caution in their long-term use. Despite these concerns, the demand for benzodiazepines remains robust due to their rapid onset of action and effectiveness.

Antidepressants, particularly SSRIs and SNRIs, have emerged as a preferred treatment option for various anxiety disorders. These medications not only address anxiety but also treat co-morbid conditions such as depression. SSRIs, such as sertraline and fluoxetine, are often considered the first-line treatment for generalized anxiety disorder and social anxiety disorder due to their favorable side effect profile and efficacy. SNRIs, such as venlafaxine and duloxetine, are also widely used and are particularly effective for patients who do not respond to SSRIs. The growing preference for antidepressants over benzodiazepines can be attributed to their lower risk of dependence and side effects.

Beta-blockers are another class of drugs used in the management of anxiety, particularly for symptoms such a

The global Anxiety Disorder and Depression Treatment market size was valued at USD XX million in 2025 and is projected to grow at a CAGR of XX% from 2025 to 2033. The increasing prevalence of anxiety disorders and depression is the primary driver of market growth. The market is segmented into applications (hospitals, clinics, and others) and types (medications, psychotherapy, and others). North America is the largest regional market and Asia-Pacific is projected to grow at the highest CAGR during the forecast period. The key players in the Anxiety Disorder and Depression Treatment market include Pfizer, Johnson & Johnson, Lundbeck, GSK, Eli Lilly, and AstraZeneca. The rising prevalence of anxiety disorders and depression is a major factor contributing to the market's growth. According to the World Health Organization, anxiety disorders and depression affect approximately 300 million and 264 million people worldwide, respectively. The increasing awareness of these mental health conditions and the availability of effective treatments are also driving market growth. Furthermore, the development of innovative treatments, such as novel medications and therapies, is expected to further fuel market expansion. However, patent expirations of certain blockbuster drugs and the stringent regulatory environment for the development and approval of new treatments may restrain market growth to some extent.

The global anxiety treatment device market is valued at USD 2.29 billion in 2025 and is expected to expand at a CAGR of 7.78% during the forecast period (2025-2033). Growing mental health disorders and the rising awareness of mental health are driving the market's growth. The increase in the prevalence of anxiety disorders, the growing adoption of advanced wearable devices, and the rising incorporation of VR/AR technologies in anxiety treatment contribute to the market's expansion. Key segments of the market include wearable devices, mobile applications, virtual reality devices, and neurostimulation devices. Cognitive Behavioral Therapy (CBT) is the dominant treatment method, followed by meditation and relaxation techniques. Individuals and clinics are the primary end-users, while the elderly population is witnessing a significant increase in anxiety disorders. North America holds the largest market share due to high healthcare spending and a large population of individuals with mental health issues. Asia-Pacific is projected to grow rapidly, driven by rising disposable income and technological advancements. Major players in the market include Soterix Medical, Electrocore, Curelator, Medtronic, BrainCo, Calm Technology, Hematogenix, eNeura, Cerebellum, Halo Neuroscience, Psybernetics, TMS NeuroHealth Centers, Fisher Wallace Laboratories, NeuroSigma, and FocusMotion. Anxiety Treatment Device Market Report Market Value The global anxiety treatment device market is valued at USD 1.5 billion in 2023 and is expected to reach USD 2.5 billion by 2030, growing at a CAGR of 6.5%. Recent developments include: , Recent developments in the Anxiety Treatment Device Market showcase a growing interest in innovative therapies and technologies designed to manage anxiety disorders. Companies such as Soterix Medical and NeuroSigma are increasingly focusing on transcranial electrical stimulation devices, leveraging advancements in neurostimulation to improve patient outcomes. Electrocore has also gained attention with its vagus nerve stimulation device, seeking to address the rising prevalence of anxiety conditions. In the realm of mergers and acquisitions, Medtronic has been actively looking for strategic partnerships to enhance its product portfolio in this sector, indicating a shift towards consolidating resources to better meet market demands. Meanwhile, Calm Technology and BrainCo are exploring collaborations to integrate mindfulness and cognitive behavioral therapy into their devices. Financially, companies like Fisher Wallace Laboratories and eNeura have reported significant growth in market valuation, reflecting a positive reception of their anxiety treatments among consumers. Current affairs illustrate not just technological advancements but also a proactive shift in market dynamics as companies adapt to the evolving needs of anxiety disorder treatments and patient care solutions. These developments signify a robust and competitive landscape within the Anxiety Treatment Device Market., Anxiety Treatment Device Market Segmentation Insights. Key drivers for this market are: Teletherapy integration for devices, Wearable anxiety monitoring solutions; Personalized treatment device development; AI-driven predictive analytics tools; Expansion in developing markets. Potential restraints include: Growing prevalence of anxiety disorders, Rising adoption of wearable devices; Technological advancements in treatment; Shift towards holistic therapies; Increased investment in mental health solutions.

The global anxiety disorders and depression treatment market size was valued at USD 674.52 Million in 2025 and is expected to grow at a compound annual growth rate (CAGR) of 3.7% from 2025 to 2033. The increasing prevalence of anxiety and depression, rising awareness about available treatment options, government initiatives to improve mental health care, and the development of novel and innovative therapies are driving market growth. The market is segmented based on treatment type, type of anxiety disorder, patient age group, and severity of condition. The pharmacological treatment segment is expected to hold the largest market share due to the widespread use of antidepressants, antipsychotics, and benzodiazepines. The psychotherapy segment is projected to witness significant growth owing to the increasing popularity of cognitive behavioral therapy (CBT), interpersonal therapy (IPT), and other non-pharmacological interventions. The moderate severity of the condition segment is anticipated to account for a major share of the market, attributed to the higher prevalence of moderate anxiety and depression. Geographically, North America is expected to dominate the market, followed by Europe and Asia-Pacific. The United States is the largest market in the region due to the high prevalence of mental disorders and well-established healthcare infrastructure. The global anxiety disorders and depression treatment market size was valued at USD 14.3 billion in 2022 and is projected to grow at a CAGR of 5.3% during the forecast period (2023-2032). Anxiety disorders and depression are common mental health conditions that affect millions of people worldwide. They can cause a range of symptoms, including feelings of anxiety, sadness, hopelessness, and worthlessness. There are a variety of effective treatments available for anxiety disorders and depression, including medication, psychotherapy, and lifestyle changes. Key drivers for this market are: Telemedicine and Digital Health Expansion Advanced Treatment Options Development PatientCentered Approach Adoption Personalized Treatment Plans Implementation Mental Health Awareness and Stigma Reduction. Potential restraints include: Increasing prevalence of anxiety disorders and depression Advancements in diagnostic and therapeutic technologies Growing awareness and destigmatization of mental health Increase in government initiatives and healthcare expenditure..

In 2020, around 33 percent of individuals in Latin America reported that at least once in their lifetime they were so anxious or depressed that they could not continue their regular daily activities as they normally would for two weeks or longer. This statistic illustrates the percentage of respondents worldwide who at some point in their life had felt so anxious or depressed that they could not continue their regular daily activities as they normally would for two weeks or longer as of 2020, by region.

In 2022, nearly 12 percent of women in Switzerland experienced anxiety disorder symptoms in the past 12 months. Meanwhile, the share of men with anxiety disorder symptoms in was 7.5 percent in the same year.

BackgroundSelf-compassion is associated with emotional well-being, yet its benefits in generalized anxiety disorder (GAD) patients remain unclear. This study investigated the impact of self-compassion on emotional and physiological stress responses in individuals diagnosed with GAD.MethodsSeventy-seven GAD patients were categorized into high (n = 39) and low (n = 38) self-compassion groups using the Self-Compassion Scale. Electrocardiograms were recorded during a stress-inducing task, in which negative feedback was provided on personal intelligence and career development. Participants reported state anxiety and perceived stress pre- and post-task.ResultsWhen exposed to a stressor, individuals with higher self-compassion had lower heart rates (t(75) = -2.06, p = 0.043), higher heart rate variability (t(75) = 2.73, p = 0.04), and lower anxiety (t(75) = -2.07, p = 0.041) compared to the lower self-compassion group. Moreover, heart rate variability was negatively correlated with anxiety across patients (r = -0.31, df = 75, p = 0.03).ConclusionThese results highlight the role of self-compassion in managing psychological and physiological responses to stress in GAD patients and indicate the potential of self-compassion interventions in GAD treatments.

Anxiety Disorder and Depression Treatment Market Outlook

The global anxiety disorder and depression treatment market size was valued at approximately USD 15 billion in 2023 and is projected to reach around USD 25 billion by 2032, expanding at a compound annual growth rate (CAGR) of 6%. The increasing prevalence of anxiety and depression worldwide is a significant factor driving market growth. Other growth factors include rising awareness about mental health, advancements in treatment options, and increasing support from government and non-government organizations.

Several factors contribute to the growth of the anxiety disorder and depression treatment market. First, the increasing prevalence of anxiety and depression worldwide is alarming. According to the World Health Organization (WHO), more than 264 million people suffer from depression globally, and anxiety disorders affect millions more. This growing prevalence is boosting the demand for effective treatment options, thereby propelling the market forward. Second, there is a rising awareness about mental health, which has led to more people seeking treatment for their conditions. Campaigns by governments, healthcare institutions, and non-governmental organizations (NGOs) are playing a critical role in breaking the stigma associated with mental health issues, encouraging individuals to seek help and thus driving market growth.

Advancements in treatment options are also significantly contributing to market expansion. Innovations in pharmaceuticals, such as the development of new classes of antidepressants and anxiolytics with fewer side effects, are enhancing treatment efficacy and patient compliance. Additionally, the growing popularity of non-pharmacological treatments, such as cognitive-behavioral therapy (CBT) and other forms of psychotherapy, is widening the treatment landscape. Technological advancements, such as telemedicine and online therapy platforms, are making mental health services more accessible, particularly in remote and underserved areas, further driving market growth.

Another crucial factor is the increasing support from both government and non-government organizations. Governments across the globe are recognizing the burden of mental health issues and are allocating more resources toward mental health care. For instance, initiatives like the Mental Health Parity and Addiction Equity Act in the United States aim to provide equal insurance coverage for mental health services. Similarly, various NGOs are working tirelessly to provide mental health support and resources, further bolstering the market for anxiety disorder and depression treatments.

Regionally, North America holds a significant share of the global anxiety disorder and depression treatment market, attributed to the high prevalence of mental health issues, advanced healthcare infrastructure, and substantial funding for mental health research. Europe follows suit, benefiting from strong healthcare systems and increasing mental health awareness. The Asia Pacific region is projected to witness the highest growth rate, driven by rising awareness, improving healthcare infrastructure, and increasing government initiatives to tackle mental health issues. Latin America and the Middle East & Africa are also showing promising growth, albeit at a slower pace, due to emerging healthcare infrastructures and growing awareness about mental health.

Treatment Type Analysis

The treatment type segment of the anxiety disorder and depression treatment market can be divided into medication, therapy, and others. Medication remains the most widely adopted treatment option for anxiety disorders and depression. This includes a range of pharmaceutical products such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), benzodiazepines, and other antidepressants. The widespread use of medication is driven by its efficacy in rapidly alleviating symptoms, ease of use, and the availability of numerous options tailored to individual patient needs. Additionally, ongoing research and development activities are continuously bringing forth new drugs with improved efficacy and reduced side effects, further bolstering the segment's growth.

Therapy, particularly cognitive-behavioral therapy (CBT), is another crucial treatment type for anxiety disorders and depression. CBT has proven highly effective in treating these conditions by helping patients identify and change negative thought patterns and behaviors. The non-invasive nature of therapy and its potential for long-term benefits make it an attractive optio

Prevalence of patients diagnosed with anxiety disorder in June 2022, by percentage.

The global online anxiety therapy market is projected to witness significant growth in the coming years, driven by rising anxiety levels, increasing awareness about mental health, and advancements in technology. The market size, valued at million in 2025, is anticipated to reach million by 2033, exhibiting a CAGR of %% during the forecast period. Factors such as the growing adoption of telehealth services, increasing acceptance of online therapy, and the availability of affordable options are contributing to the market's growth. Remote therapy platforms provide convenience, accessibility, and anonymity, appealing to individuals who face barriers to in-person therapy. Furthermore, the increasing prevalence of anxiety disorders, the stigma associated with mental health, and the need for personalized and discreet therapy services are further propelling the market's expansion. The market is segmented into applications, such as generalized anxiety disorder, social anxiety disorder, and panic disorder, and types, including cognitive behavioral therapy, mindfulness-based therapy, and exposure and response prevention therapy. Key players in the market include Talkspace, MDLive, Teladoc Health, Brightside, and BetterHelp. Regional analysis indicates robust growth across North America, Europe, Asia Pacific, and the Middle East and Africa.

Anti Anxiety Drugs Market Outlook

The global anti-anxiety drugs market size was valued at approximately USD 14 billion in 2023 and is expected to reach around USD 22 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 5.1%. One of the primary growth factors driving this market is the increasing prevalence of anxiety disorders globally, coupled with rising awareness and diagnosis of mental health conditions.

The growing awareness and acceptance of mental health issues have significantly contributed to the demand for anti-anxiety medications. As societies become more open about discussing mental health, more individuals are seeking medical help for anxiety disorders. Governments and non-profit organizations are also playing a crucial role by advocating mental health awareness, which is pivotal in reducing the stigma around these conditions. This heightened awareness is leading to early diagnosis and treatment, thereby driving the market for anti-anxiety drugs.

Technological advancements and innovations in drug delivery systems are also augmenting the growth of the anti-anxiety drugs market. Innovations such as extended-release formulations and novel drug delivery mechanisms are enhancing the effectiveness and patient compliance of these medications. Pharmaceutical companies are investing heavily in research and development to introduce drugs with fewer side effects, which can provide a better quality of life for patients. These advancements are making treatments more accessible and efficient, thereby expanding the market size.

The increasing burden of work-related stress and urbanization is another key factor contributing to the growth of the anti-anxiety drugs market. As urban areas continue to expand, the fast-paced lifestyle associated with city living often leads to higher levels of stress and anxiety. The pressure to perform in highly competitive environments, alongside financial uncertainties, further exacerbates anxiety conditions. Hence, the demand for anti-anxiety medications is rising among the urban population, contributing significantly to the market growth.

Regionally, North America holds the largest share in the anti-anxiety drugs market due to the high prevalence of anxiety disorders and the well-established healthcare infrastructure. Europe follows closely, driven by increasing healthcare expenditure and growing awareness of mental health. The Asia-Pacific region is expected to witness the highest growth rate during the forecast period, attributed to increasing urbanization, economic growth, and rising awareness about mental health. Latin America and the Middle East & Africa, though currently holding smaller market shares, are also anticipated to show gradual growth, primarily due to improving healthcare infrastructure and rising awareness about mental health issues.

Drug Class Analysis

The anti-anxiety drugs market is segmented into several drug classes, including Benzodiazepines, Antidepressants, Beta-Blockers, and Others. Benzodiazepines have historically been one of the most commonly prescribed classes of drugs for anxiety disorders due to their rapid onset of action and efficacy in reducing acute anxiety symptoms. Drugs like diazepam, lorazepam, and alprazolam fall under this category. However, their potential for dependence and side effects have led to a cautious approach in their prescription. Despite these challenges, benzodiazepines continue to hold a significant market share due to their effectiveness in treating severe and acute anxiety episodes.

Antidepressants, particularly SSRIs (Selective Serotonin Reuptake Inhibitors) and SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), are increasingly being used to manage anxiety disorders. These medications are preferred for long-term treatment as they address the underlying neurochemical imbalances associated with anxiety. Drugs like fluoxetine, sertraline, and venlafaxine are commonly prescribed SSRIs and SNRIs. The shift towards antidepressants is driven by their lower potential for abuse and better side-effect profile compared to benzodiazepines. This trend is likely to continue, contributing to the growth of the antidepressant segment in the anti-anxiety drugs market.

Beta-blockers, though traditionally used for cardiovascular conditions, are also prescribed for anxiety, particularly performance anxiety. Drugs such as propranolol help manage the physical symptoms of anxiety, such as tachycardia and tremors. The use of beta-blockers is more situational, often prescribed for short-term or specific anxiety-inducing events rather t

This is an uncertainty number, for more information see Uncertainty in data on kolada.se. Residents aged 16-84 who are bothered by anxiety and/or anxiety are an excise estimate from a sample survey. This means that the estimate is not necessarily representative of the population as a whole. However, with the point estimate ± the uncertainty number, one can most likely say that the true mean is within the range. Data is available according to gender breakdown.

ObjectiveLung cancer is a leading cause of cancer-related morbidity and mortality worldwide, with patients frequently experiencing significant psychological distress, particularly anxiety. Despite the high prevalence of anxiety in patients with cancer, there is limited comprehensive research focusing on the specific factors influencing anxiety in patients with early- and middle-stage lung cancer within the context of Chinese medicine hospitals. Therefore, we aimed to investigate the epidemiology and factors influencing anxiety disorders in patients with early- and middle-stage primary bronchial lung cancer through a cross-sectional study.MethodsA total of 340 patients with early and middle-stage lung cancer admitted to the outpatient ward of the oncology department at Guang’anmen Hospital from June 2023 to December 2023 were included in this study. Survey data, including the patients’ general condition questionnaire, Generalized Anxiety Scale (GAD-7), Hospital Anxiety and Depression Scale (HADS), and Mental Toughness Scale (CD-RISC-10), were collected and recorded in a database using a two-person input format. Data analysis was performed using SPSS 27.0 software.ResultsOut of the 340 patients with early- and middle-stage lung cancer included in this study, 133 had anxiety, resulting in an overall anxiety detection rate of 39.12%. The chi-square test showed that statistically significant differences in religion, marital status, surgical treatment, tobacco use, and alcohol history between the anxious and non-anxious groups (p